Editas Medicine, Inc. (0IFK.L)
USD 1.46
(-4.63%)
USD 1.46
(-4.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -99.52 Million USD | 438.76% |
| 2022 | 13.37 Million USD | -34.73% |
| 2021 | 20.49 Million USD | 130.46% |
| 2020 | -67.26 Million USD | 11.92% |
| 2019 | -76.36 Million USD | -30.06% |
| 2018 | -58.71 Million USD | 15.43% |
| 2017 | -69.43 Million USD | -36.34% |
| 2016 | -50.92 Million USD | -195.79% |
| 2015 | -17.21 Million USD | -239.38% |
| 2014 | -5.07 Million USD | -219.06% |
| 2013 | -1.59 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -274 Thousand USD | -100.47% |
| 2024 Q2 | -907 Thousand USD | -231.02% |
| 2024 Q3 | -1.53 Million USD | -69.57% |
| 2023 Q4 | 58.58 Million USD | 1432.78% |
| 2023 FY | 72.05 Million USD | 438.76% |
| 2023 Q1 | 8.3 Million USD | 67.51% |
| 2023 Q2 | 1.34 Million USD | -83.78% |
| 2023 Q3 | 3.82 Million USD | 183.74% |
| 2022 Q2 | 4.76 Million USD | -8.61% |
| 2022 FY | 13.37 Million USD | -34.73% |
| 2022 Q1 | 5.21 Million USD | -52.43% |
| 2022 Q4 | 4.95 Million USD | 417.48% |
| 2022 Q3 | -1.56 Million USD | -132.79% |
| 2021 Q4 | 10.95 Million USD | 147.5% |
| 2021 Q1 | -35.43 Million USD | 29.24% |
| 2021 Q2 | -33.37 Million USD | 5.82% |
| 2021 Q3 | -23.06 Million USD | 30.88% |
| 2021 FY | 20.49 Million USD | 130.46% |
| 2020 Q1 | -28.84 Million USD | -28.18% |
| 2020 FY | -67.26 Million USD | 11.92% |
| 2020 Q4 | -50.08 Million USD | -273.15% |
| 2020 Q3 | 28.92 Million USD | 267.6% |
| 2020 Q2 | -17.25 Million USD | 40.17% |
| 2019 Q3 | -18.85 Million USD | 11.21% |
| 2019 FY | -76.36 Million USD | -30.06% |
| 2019 Q4 | -22.5 Million USD | -19.36% |
| 2019 Q2 | -21.23 Million USD | -54.18% |
| 2019 Q1 | -13.77 Million USD | 48.22% |
| 2018 Q3 | -2.92 Million USD | 88.46% |
| 2018 Q4 | -26.59 Million USD | -809.68% |
| 2018 FY | -58.71 Million USD | 15.43% |
| 2018 Q1 | -17.37 Million USD | 23.66% |
| 2018 Q2 | -25.34 Million USD | -45.89% |
| 2017 FY | -69.43 Million USD | -36.34% |
| 2017 Q1 | -18.33 Million USD | 29.29% |
| 2017 Q2 | -14.22 Million USD | 22.45% |
| 2017 Q3 | -14.11 Million USD | 0.75% |
| 2017 Q4 | -22.75 Million USD | -61.24% |
| 2016 Q4 | -25.93 Million USD | -162.79% |
| 2016 FY | -50.92 Million USD | -195.79% |
| 2016 Q3 | -9.87 Million USD | -40.16% |
| 2016 Q2 | -7.04 Million USD | 12.81% |
| 2016 Q1 | -8.07 Million USD | -60.45% |
| 2015 Q2 | -7.11 Million USD | -276.85% |
| 2015 Q3 | -3.18 Million USD | 55.31% |
| 2015 Q1 | -1.88 Million USD | 21.17% |
| 2015 Q4 | -5.03 Million USD | -58.3% |
| 2015 FY | -17.21 Million USD | -239.38% |
| 2014 FY | -5.07 Million USD | -219.06% |
| 2014 Q3 | -1.25 Million USD | -76.12% |
| 2014 Q4 | -2.39 Million USD | -90.99% |
| 2014 Q2 | -712 Thousand USD | 0.0% |
| 2014 Q1 | -712 Thousand USD | 0.0% |
| 2013 FY | -1.59 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dynavax Technologies Corporation | 182.11 Million USD | 154.651% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 119.003% |
| Perrigo Company plc | 1.68 Billion USD | 105.923% |
| Illumina, Inc. | 2.74 Billion USD | 103.627% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.654% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -940.435% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.375% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 101.9% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 1091.117% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.881% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -405.244% |
| Waters Corporation | 1.76 Billion USD | 105.651% |
| Biogen Inc. | 7.3 Billion USD | 101.363% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | -119.587% |
| Evolus, Inc. | 140.52 Million USD | 170.825% |
| Adicet Bio, Inc. | -6.09 Million USD | -1532.142% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 772.759% |
| bluebird bio, Inc. | -4.03 Million USD | -2369.677% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 236.215% |
| FibroGen, Inc. | 128.9 Million USD | 177.211% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 102.872% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | -219.331% |
| Homology Medicines, Inc. | -7.22 Million USD | -1276.788% |
| Geron Corporation | -123.5 Million USD | 19.412% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 106.557% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 127.492% |
| Myriad Genetics, Inc. | 476.4 Million USD | 120.892% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -33984.932% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 75.043% |
| Zoetis Inc. | 5.83 Billion USD | 101.706% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 33056.291% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 104.589% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 105.226% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 101.156% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -32747.525% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 112.784% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -31698.083% |
| Verastem, Inc. | -62 Thousand USD | -160429.032% |
| Nektar Therapeutics | 53.47 Million USD | 286.11% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 140.701% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | -16.795% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 109.106% |
| OPKO Health, Inc. | 318.12 Million USD | 131.286% |
| Exelixis, Inc. | 1.75 Billion USD | 105.663% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 105.387% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 120.914% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| uniQure N.V. | 2.21 Million USD | 4593.363% |
| Imunon, Inc. | -720 Thousand USD | -13723.237% |
| Blueprint Medicines Corporation | 236.58 Million USD | 142.069% |
| Insmed Incorporated | 239.63 Million USD | 141.533% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 115.627% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 674.675% |
| TG Therapeutics, Inc. | 219.1 Million USD | 145.424% |
| Incyte Corporation | 3.44 Billion USD | 102.893% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 128.941% |